journal article·2022-03

Reprogramming Tumor‐Associated Macrophages via ROS‐Mediated Novel Mechanism of Ultra‐Small Cu2−xSe Nanoparticles to Enhance Anti‐Tumor Immunity

Yanhui Zheng, Yaobao Han, Tingting Wang, Hanghang Liu, Qiao Sun, Shijun Hu, Jianquan Chen, Zhen Li

Advanced Functional Materials· Volume 32· Issue 12
Publisher page

Abstract

Abstract Reprogramming tumor‐associated macrophages (TAMs) from tumor‐supportive M2 phenotype to anti‐tumor M1 phenotype holds great promise in tumor immunotherapy. However, there are few reports on the remodeling of TAMs by inorganic nanoparticles due to their unclear intrinsic polarization mechanism. In this article, a novel signaling pathway of repolarizing TAMs into M1‐like macrophages is reported to boost anti‐tumor immunity using ultra‐small Cu2−xSe nanoparticles (CS NPs). The mechanism is totally different from the conventional ROS‐mediated polarization mechanism. It is revealed that CS NPs can effectively generate ROS in the macrophages to trigger auto‐ubiquitination of tumor necrosis factor receptor‐associated factor 6 (TRAF6), which activates the interferon regulatory factor 5 (IRF5) to facilitate the expression of its downstream gene interleukin‐23 (IL‐23), and eventually remodels the TAMs into M1‐like macrophages. It is shown that CS NPs can significantly inhibit the growth of melanoma tumor (B16F10) by repolarizing TAMs into M1‐like macrophages, and enhance the adaptive anti‐tumor immunity by inducing the infiltration of CD8+ T cells. Moreover, it is found that CS NPs can also effectively inhibit the recurrence of distal tumor. The study shows the novel macrophage polarization mechanism for TAMs‐targeted cancer immunotherapy, and demonstrates the great potential of ultra‐small Cu2−xSe nanoparticles in cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Phagocytosis and Immune Regulation · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Molecular Imaging and Nuclear Medicine State Key Laboratory of Radiation Medicine and Protection School for Radiological and Interdisciplinary Sciences (RAD‐X) Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions Medical College, Soochow University Suzhou 215123 China

Department of Cardiovascular Surgery of the First Affiliated Hospital Institute for Cardiovascular Science Collaborative Innovation Center of Hematology State Key Laboratory of Radiation Medicine and Protection Medical College, Soochow University Suzhou 215006 China

Department of Orthopaedics The First Affiliated Hospital of Soochow University Suzhou Jiangsu 215006 China

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China · Jiangsu Provincial Key Research and Development Program · Suzhou Municipal Science and Technology Bureau

References (75)

Show source-provided references
1. 10.1038/s41392-020-0205-z10.1038/s41392-020-0205-z ↗
2. 10.1038/nri.2017.4910.1038/nri.2017.49 ↗
3. 10.1002/adma.20190415610.1002/adma.201904156 ↗
4. 10.1038/s41392-021-00484-910.1038/s41392-021-00484-9 ↗
5. 10.1021/acs.accounts.9b0014810.1021/acs.accounts.9b00148 ↗
6. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
7. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
8. 10.1038/nrc.2016.5410.1038/nrc.2016.54 ↗
9. 10.1002/adtp.20190018110.1002/adtp.201900181 ↗
10. 10.1038/s41467-018-03225-910.1038/s41467-018-03225-9 ↗
11. 10.1038/nature1349010.1038/nature13490 ↗
12. 10.1038/s41392-021-00506-610.1038/s41392-021-00506-6 ↗
13. 10.1038/nrd.2018.16910.1038/nrd.2018.169 ↗
14. 10.1038/s41568-019-0183-z10.1038/s41568-019-0183-z ↗
15. 10.1038/s41590-018-0292-y10.1038/s41590-018-0292-y ↗
16. 10.1016/S0952-7915(97)80190-210.1016/S0952-7915(97)80190-2 ↗
17. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
18. 10.1073/pnas.160588511310.1073/pnas.1605885113 ↗
19. 10.1016/j.addr.2019.12.00110.1016/j.addr.2019.12.001 ↗
20. 10.1002/adma.20190436410.1002/adma.201904364 ↗
21. 10.1021/acsnano.9b0299310.1021/acsnano.9b02993 ↗
22. 10.1002/adma.20190463910.1002/adma.201904639 ↗
23. 10.1021/acscentsci.9b0123510.1021/acscentsci.9b01235 ↗
24. 10.1038/s41563-018-0147-910.1038/s41563-018-0147-9 ↗
25. 10.1002/adma.20180830310.1002/adma.201808303 ↗
26. 10.1038/s41568-019-0186-910.1038/s41568-019-0186-9 ↗
27. 10.1002/adma.20190200710.1002/adma.201902007 ↗
28. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
29. 10.1021/jacs.8b1090410.1021/jacs.8b10904 ↗
30. 10.1039/C9NR01789E10.1039/C9NR01789E ↗
31. 10.1021/acsami.9b0354110.1021/acsami.9b03541 ↗
32. 10.1002/adfm.20190612810.1002/adfm.201906128 ↗
33. 10.1021/nn500211210.1021/nn5002112 ↗
34. 10.1038/s41572-018-0018-310.1038/s41572-018-0018-3 ↗
35. 10.1016/j.jtemb.2018.08.00810.1016/j.jtemb.2018.08.008 ↗
36. 10.1016/j.jneuroim.2013.03.00610.1016/j.jneuroim.2013.03.006 ↗
37. 10.1016/j.jdermsci.2012.10.00910.1016/j.jdermsci.2012.10.009 ↗
38. 10.1002/adma.20160219310.1002/adma.201602193 ↗
39. 10.1038/s41551-018-0236-810.1038/s41551-018-0236-8 ↗
40. 10.1073/pnas.130888711010.1073/pnas.1308887110 ↗
41. 10.1038/nrm126010.1038/nrm1260 ↗
42. 10.7150/ijbs.887910.7150/ijbs.8879 ↗
43. 10.1038/ni.199010.1038/ni.1990 ↗
44. 10.1155/2013/24580410.1155/2013/245804 ↗
45. 10.1038/cdd.2017.9110.1038/cdd.2017.91 ↗
46. 10.1021/acs.nanolett.8b0356810.1021/acs.nanolett.8b03568 ↗
47. 10.1002/anie.20201322810.1002/anie.202013228 ↗
48. 10.1002/adfm.20200802210.1002/adfm.202008022 ↗
49. 10.1002/adma.20190449510.1002/adma.201904495 ↗
50. 10.1038/ncomms477110.1038/ncomms4771 ↗
51. 10.1073/pnas.141851611110.1073/pnas.1418516111 ↗
52. 10.1016/j.biocel.2006.07.00110.1016/j.biocel.2006.07.001 ↗
53. 10.1093/rheumatology/keab47710.1093/rheumatology/keab477 ↗
54. 10.1038/s41598-018-36052-510.1038/s41598-018-36052-5 ↗
55. 10.4049/jimmunol.167.4.227510.4049/jimmunol.167.4.2275 ↗
56. 10.1038/srep3930310.1038/srep39303 ↗
57. 10.1007/s40200-018-0341-y10.1007/s40200-018-0341-y ↗
58. 10.1038/cr.2010.17810.1038/cr.2010.178 ↗
59. 10.1042/bj2002025610.1042/bj20020256 ↗
60. 10.1038/ncomms767610.1038/ncomms7676 ↗
61. 10.1016/j.redox.2015.08.00910.1016/j.redox.2015.08.009 ↗
62. 10.1158/0008-5472.CAN-05-408710.1158/0008-5472.CAN-05-4087 ↗
63. 10.4049/jimmunol.171.2.60010.4049/jimmunol.171.2.600 ↗
64. 10.1038/nature0330810.1038/nature03308 ↗
65. 10.1128/MCB.00662-0810.1128/MCB.00662-08 ↗
66. 10.1186/1750-2187-8-710.1186/1750-2187-8-7 ↗
67. 10.1038/s41467-017-01290-010.1038/s41467-017-01290-0 ↗
68. 10.1074/jbc.M60950320010.1074/jbc.M609503200 ↗
69. 10.1038/cr.2013.2110.1038/cr.2013.21 ↗
70. 10.1016/j.molcel.2008.09.00210.1016/j.molcel.2008.09.002 ↗
71. 10.1038/ncomms1126710.1038/ncomms11267 ↗
72. 10.1074/jbc.M112.37735810.1074/jbc.M112.377358 ↗
73. 10.4049/jimmunol.175.4.207110.4049/jimmunol.175.4.2071 ↗
74. Zhang X. · Curr. Protoc. Immunol. · 2008
75. 10.1080/2162402X.2015.111859910.1080/2162402X.2015.1118599 ↗